GLG News by Hematologists who Treat Myelodysplastic Syndromes
Articles with lock require a subscription to GLG News |
Request a free trial
May 27, 2008
So much for non-invasive surgery in prostate cancer
Analysis of: Mixed Outcomes in Laparoscopy for Prostates | www.nytimes.com
Author: GLG Expert Contributor
So much for non-invasive surgery in prostate cancerAnalysis of: Mixed Outcomes in Laparoscopy for Prostates | www.nytimes.com
Author: GLG Expert Contributor
Higher recurrance rate???!!!
May 27, 2008
Genentech, Schering-Plough,,Avant Immunotherapeutics. & Pfizer all helping with "brain cancer" therapy.
Analysis of: Hints of Progress in Drugs Treating Brain Cancer | www.nytimes.com
Author: GLG Expert Contributor
Genentech, Schering-Plough,,Avant Immunotherapeutics. & Pfizer all helping with "brain cancer" therapy.Analysis of: Hints of Progress in Drugs Treating Brain Cancer | www.nytimes.com
Author: GLG Expert Contributor
While no slam dunk cures are noted, drugs such as Avastin (Genentech), Temodar (Schering-Plough) & Avant/Pfizer vaccines are making an impact on "Brain Cancer" survival.
May 23, 2008Erbitux and Lung cancer
Analysis of: Phase II trial of gemcitabine, docetaxel, and cetuximab in advanced non-small-cell lung cancer (NSCLC). | www.abstract.asco.org
Author: Donald Fleming, Division Head of Hematology and Oncology, Davis Health System, Inc.
Erbitux has had a few high level trials in Non small lung cancer So far there does not appear to be a contributuion to chemotherapy Maybe we are going about it the wrong way
May 22, 2008
Erbitux: Alot remains to be determined re: its place in NSCLCA therapy
Analysis of: Phase II trial of gemcitabine, docetaxel, and cetuximab in advanced non-small-cell lung cancer (NSCLC). | www.abstract.asco.org
Author: GLG Expert Contributor
Erbitux: Alot remains to be determined re: its place in NSCLCA therapyAnalysis of: Phase II trial of gemcitabine, docetaxel, and cetuximab in advanced non-small-cell lung cancer (NSCLC). | www.abstract.asco.org
Author: GLG Expert Contributor
" Conclusions: Cetuximab does not appear to add to treatment efficacy when combined with gemcitabine and docetaxel in advanced NSCLC. A high rate of severe cetuximab HSRs necessitated trial closure at our Nashville site." Not very promising.
May 20, 2008
Chinese Generics?? You must be kidding!
Analysis of: China Muscles In On The Generics Industry | www.pharmalot.com
Author: GLG Expert Contributor
Chinese Generics?? You must be kidding!Analysis of: China Muscles In On The Generics Industry | www.pharmalot.com
Author: GLG Expert Contributor
Low cost generics to be produced in China will lower drug costs.
May 20, 2008
Global Cancer Market: room for further growth!
Analysis of: Global market expected to drive cancer drug growth | www.therapeuticsdaily.com
Author: GLG Expert Contributor
Global Cancer Market: room for further growth!Analysis of: Global market expected to drive cancer drug growth | www.therapeuticsdaily.com
Author: GLG Expert Contributor
As world economies improve more money will be spent globally on cancer care expanding potential markets
May 19, 2008TREANDA for CLL could be a winner
Analysis of: FDA Accepts TREANDA(R) New Drug Application for the Treatment of Relapsed Indolent Non-Hodgkin's Lymphoma | www.pipelinereview.com
Author: Brian Abbott, Medical Director of Hematology, Big Sky Oncology
The ease of use compared to fludarabine regimens, and the superior efficacy vs chlorambucil, puts TREANDA in the sweet spot for potential front-line use in CLL.
May 19, 2008National healthcare? Better find a new pool of physicians
Analysis of: Look to England's example for ways to solve America's health-care problem | www.sltrib.com
Author: Brian Abbott, Medical Director of Hematology, Big Sky Oncology
National healthcare has again become part of the presidential election dialog, after a curious 12+ year absence. Also curious, Hillary Clinton is again center stage in the discussion. Will the outcome be different this time?
May 19, 2008Medicare: heading toward a crisis
Analysis of: Loss of Doctors Leaves Patients Waiting | www.redorbit.com
Author: Brian Abbott, Medical Director of Hematology, Big Sky Oncology
The aging population, coupled with per capita decreases in Medicare spending, threatens the entire health care system. Here's why.
May 19, 2008
The gods giveth and then takith away- Go figure.....
Analysis of: First-Line Gefitinib in Patients With Advanced Non–Small-Cell Lung Cancer Harboring Somatic EGFR Mutations | jco.ascopubs.org
Author: GLG Expert Contributor
The gods giveth and then takith away- Go figure.....Analysis of: First-Line Gefitinib in Patients With Advanced Non–Small-Cell Lung Cancer Harboring Somatic EGFR Mutations | jco.ascopubs.org
Author: GLG Expert Contributor
Two papers, the one above, and http://jco.ascopubs.org/cgi/content/full/26/15/2450 reveal somewhat conflicting data on AstraZeneca's Iressa that was until now on the "back burner" due to Genentech's Tarceva, that had better response data than Iressa in separate trials On one hand the first paper points...
Previous Page : 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 Next91 to 100 of 539
More GLG News in
Healthcare
Most Popular:
Source Article | Expert Analyses
Use of Antipsychotics in Children Is Criticized
www.nytimes.com
Scientists recommend 'black box' for Avastin
www.fiercepharma.com
Are Costly Diabetes Pills Doing Any Good?
www.pharmalot.com
How a Drug Maker Tries to Outwit Generics
online.wsj.com
Use of Antipsychotics in Children Poses Risks of Adverse Effects
November 26, 2008
Avastin and clots? News to me. Black box warning? Why?
November 24, 2008
Off Label Use Can Be Prevented
November 24, 2008
Gardasil will most certainly be approved for boys
November 24, 2008
Medivations's (MDVN) Dimebon - We've Seen This Movie Before
November 24, 2008